FIELD: medicine; therapy.
SUBSTANCE: group of inventions can be used to reduce mucus viscoelasticity or sputum in a patient with excessively viscous or sticky mucus or sputum. For this purpose, mucus or sputum of said patient is brought into contact with a composition containing a protein or peptide containing a mono-cystine active center of thioredoxin in a reduced state, wherein the thioredoxin mono-cystine active center comprises an amino acid sequence selected from a group consisting of C-X-X-S (SEQ ID NO: 24), C-X-X-X (SEQ ID NO: 17), X-C-X-X-X-X (SEQ ID NO: 19), X-C-G-P-X-X (SEQ ID NO: 21), W-C-G-P-X-K (SEQ ID NO: 23), X-C-X-X-S-X (SEQ ID NO: 25), X-C-G-P-S-X (SEQ ID NO: 26) and W-C-G-P-S-K (SEQ ID NO: 27), wherein said residue C is in a reduced state, wherein said residues X are any amino acid residue other than cysteine. Also disclosed are methods, pharmaceutical compositions and use thereof for converting a disulphide bond of a target protein into a stable mixed disulphide bond, to maintain stable mixed disulphide bond, for its conversion into stable mixed disulphide bond.
EFFECT: group of inventions makes it possible to increase effectiveness of mucus or sputum liquefaction due to covalent binding with mucin cysteine at safety and good tolerance.
49 cl, 3 dwg, 3 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO THE THIOREDOXIN-1 EPITOPE, ITS PREPARATION AND APPLICATION | 2018 |
|
RU2791264C2 |
THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804772C2 |
THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804126C2 |
THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2023 |
|
RU2802944C1 |
THIOREDOXIN-1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO IT | 2018 |
|
RU2797266C2 |
MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO THE THIOREDOXIN-1 EPITOPE, ITS PREPARATION AND APPLICATION | 2018 |
|
RU2790687C2 |
PROTEIN AND VACCINE AGAINST SARS-CoV-2 INFECTION | 2020 |
|
RU2815060C1 |
MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THIOREDOXIN-1 AND ITS USE | 2016 |
|
RU2747929C2 |
IMPROVED IMMUNOGENICITY OF L2 HPV PEPTIDE | 2017 |
|
RU2743016C2 |
CYCLIC PROTEIN CONTAINING NO CYSTEINE RESIDUES | 2008 |
|
RU2486196C2 |
Authors
Dates
2021-06-24—Published
2014-03-17—Filed